<DOC>
	<DOCNO>NCT02579382</DOCNO>
	<brief_summary>The study evaluate safety , tolerability , efficacy vesatolimod ( formerly GS-9620 ) adult chronic hepatitis B ( CHB ) infection currently treat .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Efficacy Vesatolimod Combination With Tenofovir Disoproxil Fumarate ( TDF ) Adults With Chronic Hepatitis B ( CHB ) Infection Who Are Currently Not Being Treated</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Adult male female age 1865 Chronic HBV infection HBV DNA â‰¥ 2000 IU/mL screen Key Extensive bridge fibrosis cirrhosis Received oral antiviral treatment HBV prolong therapy immunemodulators biologics within 3 month screen Coinfection hepatitis C virus ( HCV ) , HIV hepatitis D virus ( HDV ) Chronic liver disease HBV Lactating pregnant female wish become pregnant course study Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HBV</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Liver Disease</keyword>
</DOC>